BioSim's contributions to the Strategic Plan of the Pharmaceutical Industry that is being negotiated with the Government propose measures such as identifying and sharing the capacities of new hospitals to carry out phase I and III trials with biosimilars, and updating the pricing model and reference prices that make it possible to “value innovation and adapt prices to the economic and industrial realities of the country.”
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
